Allergan to acquire Genesys-backed Naurex for $560 mln
Allergan plc (NYSE: AGN) has agreed to buy Naurex Inc, a biopharmaceutical company that is developing therapies for challenging disorders of the central nervous system. Under the terms of the deal, which is expected to close this year, Allergan will pay US$560 million in cash for the company. Based in Evanston, Illinois, Naurex has raised over US$160 million in venture capital funding since 2011, according to Thomson Reuters. Among its leading investors is Canadian venture capital firm Genesys Capital. Genesys is currently raising its third fund, Genesys Ventures III LP, which is targeting $150 million in committed capital.
27 July 2015•8 mins read
